Cargando…
Novel oncolytic chimeric orthopoxvirus causes regression of pancreatic cancer xenografts and exhibits abscopal effect at a single low dose
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) has been increasing by 0.5% per year in the United States. PDAC portends a dismal prognosis and novel therapies are needed. This study describes the generation and characterization of a novel oncolytic chimeric orthopoxvirus for the treatment of pa...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5918769/ https://www.ncbi.nlm.nih.gov/pubmed/29699566 http://dx.doi.org/10.1186/s12967-018-1483-x |
_version_ | 1783317486448410624 |
---|---|
author | O’Leary, Michael P. Choi, Audrey H. Kim, Sang-In Chaurasiya, Shyambabu Lu, Jianming Park, Anthony K. Woo, Yanghee Warner, Susanne G. Fong, Yuman Chen, Nanhai G. |
author_facet | O’Leary, Michael P. Choi, Audrey H. Kim, Sang-In Chaurasiya, Shyambabu Lu, Jianming Park, Anthony K. Woo, Yanghee Warner, Susanne G. Fong, Yuman Chen, Nanhai G. |
author_sort | O’Leary, Michael P. |
collection | PubMed |
description | BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) has been increasing by 0.5% per year in the United States. PDAC portends a dismal prognosis and novel therapies are needed. This study describes the generation and characterization of a novel oncolytic chimeric orthopoxvirus for the treatment of pancreatic cancer. METHODS: After chimerization and high-throughput screening, CF33 was chosen from 100 new chimeric orthopoxvirus isolates for its ability to kill pancreatic cancer cells. In vitro cytotoxicity was assayed in six pancreatic cancer cell lines. In vivo efficacy and toxicity were evaluated in PANC-1 and MIA PaCa-2 xenograft models. RESULTS: CF33 caused rapid killing of six pancreatic cancer cells lines in vitro, releasing damage-associated molecular patterns, and regression of PANC-1 injected and non-injected distant xenografts in vivo after a single low intratumoral dose of 10(3) plaque-forming units. Using luciferase imaging, CF33 was noted to preferentially replicate in tumors which corresponds to the low viral titers found in solid organs. CONCLUSION: The low dose of CF33 required to treat pancreatic cancer in this preclinical study may ease the manufacturing and dosing challenges currently facing oncolytic viral therapy. |
format | Online Article Text |
id | pubmed-5918769 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-59187692018-04-30 Novel oncolytic chimeric orthopoxvirus causes regression of pancreatic cancer xenografts and exhibits abscopal effect at a single low dose O’Leary, Michael P. Choi, Audrey H. Kim, Sang-In Chaurasiya, Shyambabu Lu, Jianming Park, Anthony K. Woo, Yanghee Warner, Susanne G. Fong, Yuman Chen, Nanhai G. J Transl Med Research BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) has been increasing by 0.5% per year in the United States. PDAC portends a dismal prognosis and novel therapies are needed. This study describes the generation and characterization of a novel oncolytic chimeric orthopoxvirus for the treatment of pancreatic cancer. METHODS: After chimerization and high-throughput screening, CF33 was chosen from 100 new chimeric orthopoxvirus isolates for its ability to kill pancreatic cancer cells. In vitro cytotoxicity was assayed in six pancreatic cancer cell lines. In vivo efficacy and toxicity were evaluated in PANC-1 and MIA PaCa-2 xenograft models. RESULTS: CF33 caused rapid killing of six pancreatic cancer cells lines in vitro, releasing damage-associated molecular patterns, and regression of PANC-1 injected and non-injected distant xenografts in vivo after a single low intratumoral dose of 10(3) plaque-forming units. Using luciferase imaging, CF33 was noted to preferentially replicate in tumors which corresponds to the low viral titers found in solid organs. CONCLUSION: The low dose of CF33 required to treat pancreatic cancer in this preclinical study may ease the manufacturing and dosing challenges currently facing oncolytic viral therapy. BioMed Central 2018-04-26 /pmc/articles/PMC5918769/ /pubmed/29699566 http://dx.doi.org/10.1186/s12967-018-1483-x Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research O’Leary, Michael P. Choi, Audrey H. Kim, Sang-In Chaurasiya, Shyambabu Lu, Jianming Park, Anthony K. Woo, Yanghee Warner, Susanne G. Fong, Yuman Chen, Nanhai G. Novel oncolytic chimeric orthopoxvirus causes regression of pancreatic cancer xenografts and exhibits abscopal effect at a single low dose |
title | Novel oncolytic chimeric orthopoxvirus causes regression of pancreatic cancer xenografts and exhibits abscopal effect at a single low dose |
title_full | Novel oncolytic chimeric orthopoxvirus causes regression of pancreatic cancer xenografts and exhibits abscopal effect at a single low dose |
title_fullStr | Novel oncolytic chimeric orthopoxvirus causes regression of pancreatic cancer xenografts and exhibits abscopal effect at a single low dose |
title_full_unstemmed | Novel oncolytic chimeric orthopoxvirus causes regression of pancreatic cancer xenografts and exhibits abscopal effect at a single low dose |
title_short | Novel oncolytic chimeric orthopoxvirus causes regression of pancreatic cancer xenografts and exhibits abscopal effect at a single low dose |
title_sort | novel oncolytic chimeric orthopoxvirus causes regression of pancreatic cancer xenografts and exhibits abscopal effect at a single low dose |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5918769/ https://www.ncbi.nlm.nih.gov/pubmed/29699566 http://dx.doi.org/10.1186/s12967-018-1483-x |
work_keys_str_mv | AT olearymichaelp noveloncolyticchimericorthopoxviruscausesregressionofpancreaticcancerxenograftsandexhibitsabscopaleffectatasinglelowdose AT choiaudreyh noveloncolyticchimericorthopoxviruscausesregressionofpancreaticcancerxenograftsandexhibitsabscopaleffectatasinglelowdose AT kimsangin noveloncolyticchimericorthopoxviruscausesregressionofpancreaticcancerxenograftsandexhibitsabscopaleffectatasinglelowdose AT chaurasiyashyambabu noveloncolyticchimericorthopoxviruscausesregressionofpancreaticcancerxenograftsandexhibitsabscopaleffectatasinglelowdose AT lujianming noveloncolyticchimericorthopoxviruscausesregressionofpancreaticcancerxenograftsandexhibitsabscopaleffectatasinglelowdose AT parkanthonyk noveloncolyticchimericorthopoxviruscausesregressionofpancreaticcancerxenograftsandexhibitsabscopaleffectatasinglelowdose AT wooyanghee noveloncolyticchimericorthopoxviruscausesregressionofpancreaticcancerxenograftsandexhibitsabscopaleffectatasinglelowdose AT warnersusanneg noveloncolyticchimericorthopoxviruscausesregressionofpancreaticcancerxenograftsandexhibitsabscopaleffectatasinglelowdose AT fongyuman noveloncolyticchimericorthopoxviruscausesregressionofpancreaticcancerxenograftsandexhibitsabscopaleffectatasinglelowdose AT chennanhaig noveloncolyticchimericorthopoxviruscausesregressionofpancreaticcancerxenograftsandexhibitsabscopaleffectatasinglelowdose |